Myriad Genetics Inc (NASDAQ:MYGN)
| 26.68 Delayed Data As of Jan 22 |  -0.02 / -0.07%Today’s Change | 9.24 Today|||52-Week Range 30.13 | +34.92% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.0B |
Company Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Contact Information
Myriad Genetics, Inc. 320 Wakara Way Salt Lake City Utah 84108 |
Employees
Shareholders
| Individual stakeholders | 6.29% |
| Other institutional | 53.95% |
| Mutual fund holders | 46.36% |
Top Executives
| Paul J. Diaz | President, Chief Executive Officer & Director |
| R. Bryan Riggsbee | Chief Financial Officer, Treasurer & Executive VP |
| Robert Gardner Harrison | Chief Information Officer |
| Jerry S. Lanchbury | Chief Scientific Officer |
| Clivetty Martinez | Chief Compliance Officer |
